RIPPLES from the tragic death last autumn of a young gene therapy patient,
Jesse Gelsinger, are still being felt across the US
(see p 5). First it emerged
that many gene therapy researchers had not been sending details of treatment
side effects to the US government’s Recombinant DNA Advisory Committee, the
public forum for gene therapy.
This may have been a bureaucratic glitch. But when Gelsinger’s father
announced that his son had not been told the full risks of his treatment, and
that the lead researcher in the case had a financial interest in the therapy,
the public cried…
